OncoMatch/Clinical Trials/NCT06455917
TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients
Is NCT06455917 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TILs（Tumor Infiltrating Lymphocytes） for non-small cell lung cancer.
Treatment: TILs（Tumor Infiltrating Lymphocytes） — Aim of the study is to investigate the efficacy and safety of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with advanced pre-treated non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Disease progression after at least one standard therapy and without any approved curative-intended treatment option.
Lab requirements
Blood counts
adequate hematological function per investigator's judgment
Kidney function
adequate renal function per investigator's judgment
Liver function
adequate hepatic function per investigator's judgment
Cardiac function
adequate cardiovascular function per investigator's judgment; cardiac stress testing required for all patients with underlying cardiac conditions and patients with age ≥ 50 years
Adequate organ function (pulmonary, cardiovascular, hematological, hepatic, and renal function) per investigator's judgment. Cardiac stress testing is required for all patients with underlying cardiac conditions and patients with age ≥ 50 years.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify